Webinar: Novel safety assessment of antiviral nucleoside analogues using ToxTracker
30-06-2022 to 30-06-2022
About the webinar
Nucleoside analogues are an important class of antiviral agents now commonly used in the therapy of various viral diseases, including HIV, hepatitis and herpes. More recently, antiviral nucleoside analogues have also been applied to battle SARS-CoV-2. However, due to their mode-of-action, many antiviral nucleosides induce severe toxicity and can lead to gene mutations and genome instability.
To get a better understanding of their genotoxic properties, a broad selection of antiviral nucleosides was investigated in the ToxTracker assay. ToxTracker is a stem cell-based New Approach Method (NAM) for genotoxicity assessment that provides insight into the mode-of-action of tested chemicals and substances. In this ToxTracker case study, many early nucleoside analogues were shown to be genotoxic, including Zidovudine, which was developed for HIV treatment. In contrast, newer nucleoside analogues such as Remdesivir and Molnupiravir that have been approved for emergency treatment of Covid-19 did not show any genotoxic properties in ToxTracker. During this webinar we will share the background, details and conclusions for the nucleoside analogues ToxTracker case study.
During this webinar, you will learn: